SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

STRO

Sutro Biopharma, Inc.
BEARISH
Impact 5/10
Horizonweeks Processed4d 10h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▼ Bearish

Revenue missed consensus by a wide margin, driven by lower collaboration revenue. The EPS beat is not meaningful given the different share count and expense base. Monitor upcoming clinical data for STRO-004 and STRO-006 in H1/H2 2027 as key catalysts; the cash runway into H1 2028 provides a buffer but does not offset the revenue shortfall.

DirectionBearish
Confidencehigh
Horizonweeks

Drugs in focus

STRO drug pipeline →

STRO-004

● Neutral Named in this press release
Impact
Phase
Phase 1
Time to market
Still in Phase 1 dose escalation; assuming successful Phase 1/2 and pivotal trials, potential approval would be several years away, likely 2029 or later.
Next catalyst
None dated

What to watchThe Phase 1 dose-escalation data from August 2026 showed early signals of activity (confirmed and unconfirmed partial responses) but also dose-limiting toxicities at the highest dose. The next update in H1 2027 will include expansion cohorts and more mature efficacy/safety data. Investors should watch for the dose selected for expansion, the durability of responses, and whether the safety profile supports a competitive advantage over the approved tissue-factor ADC Tivdak (tisotumab vedotin).

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$9.82
T+0 close · Nov 12, 2026 · via day close
Latest settled
−5.09%
T+1 · $9.32
Vs SPY
−3.18%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $9.82entry
  2. T+1 · 20h ago −5.09%α −3.18% · $9.32
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Sutro Biopharma reported Q3 2026 revenue of $9.1M (below the $14.1M consensus) and GAAP EPS of -$1.90 (better than the -$1.96 consensus, but on a different share count basis). The company highlighted clinical progress for STRO-004 and STRO-006, a $10M milestone from Astellas, and a cash runway into H1 2028. Revenue missed consensus, while the EPS beat is largely a function of lower operating expenses and a higher share count.

Key Financial Metrics

EPS
−$1.90
est −$1.96 · +3.1%
Revenue
$9.1M
est $14.1M · -35.5% · -6.1% YoY
Rating
in line

Key Facts

  • Q3 2026 revenue $9.1M vs consensus $14.1M (miss)
  • GAAP EPS -$1.90 vs consensus -$1.96 (beat on different basis; GAAP net loss $31.5M)
  • Cash, cash equivalents and marketable securities $142.2M as of Sep 30, 2026
  • Astellas dosed first patient in second dual-payload iADC program, triggering $10M milestone payment
  • STRO-004 Phase 1 STRIVE-01 study advancing; next update and expansion cohorts expected H1 2027
  • STRO-006 entered clinic with first patient dosed; initial update expected H2 2027
  • STRO-227 advancing toward Phase 1 initiation in early 2027
  • R&D and G&A expenses $31.0M vs $48.6M in prior year quarter
  • Net loss per share improved to -$1.90 from -$6.66 due to lower expenses and higher share count

Financial Impact

Revenue miss of ~$5M vs consensus; cash burn of ~$22M in Q3; $10M milestone received from Astellas

revenueepscash

Risk Factors

  • Revenue miss vs consensus may pressure the stock near-term
  • Clinical-stage biotech with no approved products; pipeline setbacks could materially impact valuation
  • Cash burn rate; reliance on collaboration milestones for non-dilutive funding
  • Deferred royalty obligation of $249M creates a significant liability

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402272

Track record

8 reports on STRO

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +50.74% at T+20 after the Mar 23, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Bearish 5/10 Viewing Entry $9.82 to $9.32 Now $9.32 +5.09% ▲ +5.09% +3.18% vs SPY
  2. Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $10.61 to $10.17 Now $9.32 −12.16% ▼ −4.15% −3.78% vs SPY
  3. Aug 12, 202613w ago 8-K Bullish 7/10 No price data
  4. Aug 12, 202613w ago Press Release Mixed 6/10 Entry $21.30 to $21.31 Now $9.32 −56.24% ▲ +0.05% −0.65% vs SPY
  5. Apr 22, 202629w ago DEFA14A Neutral 3/10 Entry $34.83 to $33.33 Now $9.32 −73.24% ▼ −4.31% −5.09% vs SPY
  6. Apr 19, 202630w ago Press Release Bullish 7/10 Entry $34.58 to $34.35 Now $9.32 −73.05% ▼ −0.67% −0.01% vs SPY
  7. Mar 23, 202634w ago S-3 Bearish 6/10 Entry $23.57 to $23.50 Now $9.32 +60.46% ▲ +0.30% +0.86% vs SPY
  8. Mar 23, 202634w ago Press Release Bullish 7/10 Entry $23.57 to $23.50 Now $9.32 −60.46% ▼ −0.30% −0.86% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026